Gemcitabine Hydrochloride

製品コードS1149 バッチS114910

印刷

化学情報

Chemical Structure Synonyms NSC 613327 HCl,LY-188011 HCl Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C9H11F2N3O4.HCI
分子量 299.66 CAS No. 122111-03-9
Solubility (25°C)* 体外 Water 59 mg/mL (196.88 mM)
DMSO Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 ゲムシタビンは、DNA合成および修復を阻害し、細胞のオートファジーとアポトーシスを誘導するピリミジンヌクレオシド類似体の抗腫瘍薬です。主に膵臓がんや非小細胞肺がんなどの様々な固形腫瘍の治療に使用され、効果を高めるために化学療法と併用されることがよくあります。
in vitro Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48 hours results in a dose-dependent increase in NF-κB binding. In contrast, NF-κB DNA binding is decreased in BxPC-3 cells treated with the higher Gemcitabine doses for 48 h; however, 24-h treatment with these higher doses increases NF-κB binding in BxPC-3 cells [2]
in vivo Intratumoral NF-κB activity is significantly elevated (1.3- to 1.8-fold) in the Gemcitabine-treated mice compared to the PBS-treated mice, suggesting that Gemcitabine also induces NF-κB activation. [2]
特徴 Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

プロトコル(参考用のみ)

細胞アッセイ 細胞株 BxPC-3, MIA PaCa-2, and PANC-1 cells
濃度 0.2 μM
反応時間 24 hours or 48 hours
実験の流れ BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate. After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine for an additional 24 hours or 48 hours. Apoptosis is quantified using the Cell Death Detection ELISA to detect the amount of cytoplasmic histone-associated DNA fragments and expressed relative to vehicle-treated cells.
動物実験 動物モデル Athymic nude mice with MIA PaCa-2 cells
投薬量 50 mg/kg or 100 mg/kg
投与方法 Administered via i.p.

参考

  • https://pubmed.ncbi.nlm.nih.gov/12138244/
  • https://pubmed.ncbi.nlm.nih.gov/22618517/
  • https://pubmed.ncbi.nlm.nih.gov/22590527/

カスタマーフィードバック

Data from [Data independently produced by Nucleic Acids Res, 2014, 42(10), 6436-47]

Data from [Cancer Immunol Immunother, 2013, 62, 383–391]

Data independently produced by , , Dr. Helen Sadik of Johns Hopkins University

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer [ Cancer Cell, 2025, S1535-6108(25)00271-5] PubMed: 40712568
Dynamic regulation of integrin β1 phosphorylation supports invasion of breast cancer cells [ Nat Cell Biol, 2025, 27(6):1021-1034] PubMed: 40419795
Senescence-associated lysosomal dysfunction impairs cystine deprivation-induced lipid peroxidation and ferroptosis [ Nat Commun, 2025, 16(1):6617] PubMed: 40731111
Pancreatic cancer-derived extracellular vesicles remodel the tumor microenvironment and enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblasts [ Mol Ther, 2025, S1525-0016(25)00027-9] PubMed: 39810420
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer [ NPJ Precis Oncol, 2025, 9(1):306] PubMed: 40885787
NIR pH-Responsive PEGylated PLGA Nanoparticles as Effective Phototoxic Agents in Resistant PDAC Cells [ Polymers (Basel), 2025, 17(8)1101] PubMed: 40284366
UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT [ Int J Biol Sci, 2024, 20(4):1389-1409] PubMed: 38385072
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages [ NPJ Precis Oncol, 2024, 8(1):246] PubMed: 39478186
A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer [ Phytomedicine, 2024, 155377] PubMed: none
Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer [ Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00939-5] PubMed: 38619751

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。